Get the Stockscreener App
25.32
1.63%
-0.42
Agios Pharmaceuticals Inc stock is traded at $25.32, with a volume of 968.81K.
It is down -1.63% in the last 24 hours and down -10.69% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
See More
Previous Close:
$25.74
Open:
$25.57
24h Volume:
968.81K
Relative Volume:
0.97
Market Cap:
$1.48B
Revenue:
$54.03M
Net Income/Loss:
$-412.78M
P/E Ratio:
-3.5567
EPS:
-7.1189
Net Cash Flow:
$-377.29M
1W Performance:
-27.95%
1M Performance:
-10.69%
6M Performance:
-41.56%
1Y Performance:
-13.47%
1-Day Range:
$24.92
$25.59
1-Week Range:
$24.92
$29.70
52-Week Range:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
25.32 | 1.48B | 54.03M | -412.78M | -377.29M | -7.1189 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Reiterated | H.C. Wainwright | Buy |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
BofA Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO) - Insider Monkey
Q3 2025 Agios Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
10 Oversold Small Cap Stocks to Buy Now - insidermonkey.com
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Agios (AGIO) Q2 2025 Earnings Call Transcript - AOL.com
[ARS] AGIOS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Agios Pharmaceuticals (NASDAQ: AGIO) outlines 2026 virtual meeting, director elections and plan amendment - Stock Titan
Do Upbeat EPS Revisions Before Earnings Quietly Reframe Agios Pharmaceuticals’ (AGIO) Risk‑Reward Profile? - Yahoo Finance
Do Agios Pharmaceuticals’ (AGIO) EPS Revisions Hint At A Turning Point In Its Investment Story? - simplywall.st
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) - Yahoo Finance
FY2027 Earnings Forecast for AGIO Issued By HC Wainwright - MarketBeat
Here's why Agios Pharmaceuticals crashed 23% today - MSN
Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to Decline - Yahoo Finance
Agios Pharmaceuticals (AGIO) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Bank of America Cuts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $41.00 - MarketBeat
Agios: Novo's Sickle Cell Win Changes The PK Activator Game (Rating Downgrade) - Seeking Alpha
Agios Stock Sinks 23% as NVO's PKR Activator Meets Goal in SCD Study - Yahoo Finance
H.C. Wainwright cuts Agios Pharma price target to $50 on competition - Investing.com Canada
Why Novo Nordisk's Surprise Win Hammered Agios Pharmaceuticals Stock - Investor's Business Daily
Novo Nordisk Shows Sickle Cell Efficacy Advantage Over Agios’s Mitapivat - Citeline News & Insights
Novo’s Once-Daily Sickle Cell Pill Hits Milestone. A Smaller Rival Is Sinking 24%. - Barron's
Agios Pharmaceuticals stock tumbles 25% after Novo data - Investing.com
Agios Pharmaceuticals (AGIO) Sees Significant Decline in Stock P - GuruFocus
Agios Pharmaceuticals (AGIO) Experiences Significant Decline - GuruFocus
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Cuts Target Price to $50 - Moomoo
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap DownHere's Why - MarketBeat
Here's Why Agios Pharmaceuticals Crashed 23% Today - Yahoo Finance
Here's Why Agios Pharmaceuticals Crashed 23% Today - The Motley Fool
Novo’s Forma acquisition pays off with mitapivat competitor - BioWorld News
Leerink reiterates Agios Pharma stock rating amid rival drug data By Investing.com - Investing.com Canada
US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results - Benzinga
Agios Pharmaceuticals stock tumbles 25% after Novo data By Investing.com - Investing.com South Africa
Agios falls as Novo posts late-stage trial win for sickle cell disease therapy (update) - Seeking Alpha
(AGIO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Agios Pharmaceuticals leukemia drug gets U.S. approval - AOL.com
A Look At Agios Pharmaceuticals (AGIO) Valuation As PYRUKYND Growth Prospects Face Mixed Signals - Sahm
Trend Review: Will Agios Pharmaceuticals Inc face regulatory challengesQuarterly Growth Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Valuation Update: Is Agios Pharmaceuticals Inc stock good for income investorsExit Point & Fast Moving Stock Trade Plans - baoquankhu1.vn
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - ADVFN
Agios gains on plans to seek FDA accelerated nod for Pyrukynd label expansion - MSN
AGIO Forecast, Price Target & Analyst Ratings | AGIOS PHARMACEUTICALS INC (NASDAQ:AGIO) - ChartMill
Rep. Gilbert Ray Cisneros, Jr. Buys Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock - MarketBeat
Published on: 2026-04-10 10:39:14 - baoquankhu1.vn
Exit Recap: Is Agios Pharmaceuticals Inc stock good for income investors2026 Macro Impact & Fast Moving Trade Plans - baoquankhu1.vn
What Agios Pharmaceuticals (AGIO)'s FDA-Backed Accelerated Path for Mitapivat in Sickle Cell Disease Means For Shareholders - Sahm
Agios Pharma (AGIO) Receives a Buy from Bank of America Securities - The Globe and Mail
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $44 - Moomoo
(AGIO) Risk Channels and Responsive Allocation - Stock Traders Daily
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today - AOL.com
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.01%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):